I am principal investigator in the group and a professor of clinical oncology. Apart from being a group leader, I work as a chief physician of the Clinical Trial Unit at the Department of Oncology of the Helsinki University Hospital Comprehensive Cancer Center. I believe that combination of clinical and molecular approaches is pivotal in understanding resistance mechanisms and prognosis and to discover new tools for optimal cancer therapies.
I am a senior researcher with expertise in molecular and cellular cancer biology. My research interests include the molecular mechanisms behind treatment resistance of B-cell lymphoma. Currently, I am characterizing the tumor immune microenvironment and its impact on lymphoma survival.
I am a medical oncologist focused on lymphomas, testicular cancer and osteosarcoma. My research interests include the biological mechanisms of testicular lymphoma and its tendency of central nervous system homing. Additionally, I’m interested in the molecular biology of testicular cancer with the aim of reducing treatment toxicity.
I am a specialist in oncology and my main research focus is on genetic alterations and prognostic biological factors of diffuse large B-cell lymphomas. I am also involved in conducting clinical lymphoma trials with novel and risk-adapted therapies.
I am a medical oncologist with main interest in lymphomas and clinical trials. My research projects focus on tumor immunology and aggressive extranodal lymphomas, especially testicular diffuse large B-cell lymphoma and primary central nervous system lymphoma. In addition to research, I work in Tampere University Hospital, Tays Cancer Center and Tays early phase clinical trial unit.
I am working on the molecular alterations behind diffuse large B-cell lymphoma. I am interested in the use of liquid biopsy in monitoring and predicting the disease as well as the genetics behind drug resistant cancer clones. I aim to expand the use of liquid biopsy from research to the clinics.
My research focuses on tumor microenvironment of diffuse large B-cell lymphoma. I am interested in immunological factors that have an impact on patient survival.
I am a medical oncologist in training. My research projects focus on molecular and genomic characterization of the tumor microenvironment in nodular lymphocyte predominant Hodgkin's lymphoma with a special interest in factors driving disease progression and transformation. In addition, I´m currently conducting a nationwide, population-based epidemiological assessment of all lymphomas in Finland.
I am a medical oncologist and working in the Helsinki University Hospital Comprehensive Cancer Center. My study focuses on clinical and biological prognostic factors in primary and relapsed Hodgkin lymphoma. I am especially interested in the composition of the tumor microenvironment, the interactions between neoplastic and benign cells therein, and the immunological mechanisms associating with the treatment resistance.
My projects integrate genetic alterations of diffuse large B-cell lymphoma with clinical and biological characteristics of the disease. These projects aim to recognize clinically relevant mutations from patient plasma (ctDNA sequencing) and elucidate their functional impact on drug resistance and molecular pathogenesis of the disease.
I started working in the Lymphoma Biology and Survival Group at the end of 2009 as a laboratory technician.